Prophylactic Gabapentin in HNC

MASCC/ISOO
Annual Meeting on Supportive Care in Cancer
www.mascc.org/meeting

Follow us on Twitter: @CancerCareMASCC

#MA2019
Conflict of Interest Disclosure
Derek Smith, DDS, PhD

Has no real or apparent conflicts of interest to report.
Gabapentin has been used in many settings for the treatment of pain and associated systemic symptoms. Retrospective reports indicate that prophylactic gabapentin during chemoradiation may decrease frequency and severity of pain. We undertook a randomized trial to confirm benefit in head and neck cancer patients undergoing chemoradiation.
Trial Design:

Patient population:
- Biopsy proven cancer involving the larynx, pharynx, oral cavity, paranasal sinuses or salivary gland
- Planned for either definitive or adjuvant chemoradiation
- Minimum of T2N0M0

Randomization:
- Arm 1: Standard of care (SOC) supportive measures exclusive of gabapentin until completion of radiation
- Arm 2: SOC PLUS prophylactic gabapentin starting day 1 of radiation with escalation as tolerated
  - Week 1: 100 mg po tid
  - Week 2: 300 mg po tid
  - Week 3: 600 mg po tid
  - Week 4: 900 mg po tid
Specific Aims:

Primary Aim:
- To determine whether prophylactic gabapentin can reduce the incidence and/or severity of pain in patients undergoing chemoradiation
- Measure: VHNSS v2 pain score

Secondary Aims:
- To determine whether prophylactic gabapentin can reduce the incidence and/or severity of systemic symptoms associated with chemoradiation
  - Examples: fatigue, sleep, neurocognitive changes, anxiety and depression
- To determine whether prophylactic gabapentin can reduce the incidence and/or severity of local symptoms associated with chemoradiation
  - Examples: Swallow function, mucosal burning and or sensitivity, smell and taste
Statistical Considerations:

Planned Enrollment:
- Planned accrual goal: 125 patients
- Planned interim analysis when 75 patients had completed the study

Interim Analysis: (n=79, enrolled)
- Positive for primary and secondary endpoints
- Study closed to accrual

Statistical Methods:
- Items were divided into subscales as defined as in Cooperstein et al. which developed the VHNSS 2.0
- First non-negative principle component used as subscale score
- All analyses performed using ordinal logistic regression (proportional odds model)
**Patient Characteristics:**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control</th>
<th>Gabapentin</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender - Male</td>
<td>67.7%</td>
<td>58.47%</td>
<td>0.70</td>
</tr>
<tr>
<td>Age – Median</td>
<td>57.3 yrs</td>
<td>58.5 yrs</td>
<td>0.95</td>
</tr>
<tr>
<td>Stage T</td>
<td></td>
<td></td>
<td>0.13</td>
</tr>
<tr>
<td>Stage N</td>
<td></td>
<td></td>
<td>0.26</td>
</tr>
<tr>
<td>Pre-treatment weight</td>
<td>93.2 KG</td>
<td>88.8 KG</td>
<td>0.48</td>
</tr>
<tr>
<td>P16 Status (tested routinely only in OPC)</td>
<td>83.3%</td>
<td>80.8%</td>
<td>1.0</td>
</tr>
<tr>
<td>Surgery</td>
<td>24.2%</td>
<td>19.5%</td>
<td>0.836</td>
</tr>
</tbody>
</table>
Toxicity:

Severe Adverse Events:
- None

Titration:
- Most patients on the treatment arm stayed at the 300mg tid dosage
- Major side effect preventing upward titration: fatigue and sedation

Withdrawals:
- 6 patients either withdrew or were withdrawn from the study (4 Control, 2 Treatment)
- Most withdraws were prior to the baseline visit and initiation of drug
- Only 1 patient withdrew mid-study due to drowsiness
Primary Aim:

Items:
- Average pain
- Worst pain
- Pain relief
- Pain causing difficulty sleeping
Secondary Aims:

- Decreased desire to eat
- Decreased food eaten
- Burning pain in lining of throat*
- Sensitive to dryness*
- Burning pain prevents tooth brushing

* marginal significance
Secondary Aim: General Symptoms

- Unexplained fatigue
- Problems staying asleep
- Unexplained sweating
- Feel sad or depressed
- Feel anxious
Temporal Changes

Difference between the average symptom trajectory of patients on SOC (black) vs. SOC+gabapentin (blue) over the course of therapy.
Strengths and Limitations:

Strengths:
- Measurement tools were developed specifically for head and neck cancer patients
- Items were carefully designed to capture the symptom experience of this population
- Symptoms were captured weekly

Weaknesses:
- The trial was not placebo controlled. There is a known placebo effect in trials assessing efficacy of pharmaceutical and non-pharmaceutical intervention for the treatment of pain. Whether this is true for prophylactic interventions is unknown.
- This was a single institutional study with all of the associated limitations thereof.
Conclusions:

Prophylactic use of gabapentin decreased the development and/or severity of pain in HNC patients undergoing chemoradiation compared to standard supportive care.

Prophylactic use of gabapentin decreased the development and/or severity of general systemic symptoms in HNC patients undergoing chemoradiation compared to standard supportive care.

Prophylactic use of gabapentin decreased the development and/or severity of neurosensory symptoms in HNC patients undergoing chemoradiation compared to standard supportive care.
Questions?